Kiniksa Pharmaceuticals
KNSA79.5201.73% ( -1.400 )
Q2 FY2026 EarningsQ2 2026 total revenue reached $243.6M, up 55.4% YoY, driven entirely by ARCALYST product sales. Net income rose to $25.4M with diluted EPS of $0.30. Operating expenses scaled to $216.4M (+58.4% YoY) due to higher collaboration costs and R&D investment for KPL-387. The company raised FY2026 ARCALYST sales guidance to $980M - $995M and maintains a cash position of $525.9M with no debt.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Kiniksa Pharmaceuticals(KNSA) predict that the Revenue is 243.6 M (+55.36%), Beat estimate;the EBIT is 27.19 M (+34.89%), Miss estimate;the EPS is 0.3 (+30.43%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.24B55.36%
0.23B44.43%
+0.02B10.93%
EBITMiss expectations
0.03B34.89%
0.03B60.94%
-0.01B26.05%
EPSExceed expectations
0.330.43%
0.287725.10%
+0.01235.33%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf